Esketamine medications for Major Depressive Disorder (MDD) are primarily known for the drug Spravato, manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1]. Spravato is an N-methyl-D-aspartate (NMDA) receptor antagonist and is available as a nasal spray [1][2]. It is approved for treatment-resistant depression and depressive symptoms in adults with MDD, in conjunction with an oral antidepressant [1].
Who Makes Esketamine Nasal Spray?
Janssen Pharmaceuticals, part of Johnson & Johnson, is the manufacturer of Spravato [1].
How Does Esketamine Work for Depression?
Esketamine functions as an NMDA receptor antagonist [1]. Its mechanism of action is thought to involve rapid modulation of glutamatergic signaling and synaptogenesis, leading to antidepressant effects that differ from traditional antidepressants [3].
When Does Spravato's Patent Protection End?
Information regarding the specific patent expiry dates for Spravato is often dynamic and subject to legal challenges. DrugPatentWatch.com tracks patent information and potential generic entry dates for various medications, including Spravato [4]. Patent terms can be extended or challenged, influencing the timeline for generic availability.
Are There Generic Versions of Spravato Available?
As of now, there are no FDA-approved generic versions of Spravato available [5]. The exclusivity period for brand-name drugs, along with patent protections, dictates when generic alternatives can be introduced to the market.
What Are the Safety Concerns with Esketamine Nasal Spray?
Spravato carries significant safety warnings, including a risk of sedation, dissociation, and abuse/misuse [1]. It is administered in a certified healthcare setting and patients must be monitored for at least two hours after administration [1]. Potential side effects include increased blood pressure, urinary tract issues, and nausea [1].
How Does Esketamine Compare to Other Depression Treatments?
Esketamine offers a different therapeutic approach compared to traditional antidepressants, which primarily target monoamine systems [3]. Its rapid onset of action is a key distinguishing factor. However, it is typically used as an adjunct therapy and requires specific administration protocols due to its safety profile [1][3].
What is the Cost of Esketamine Treatment?
The cost of esketamine treatment can be substantial and varies based on insurance coverage and treatment duration. Patients often face out-of-pocket expenses for the medication and administration in a certified clinic [6].
---
Sources:
[1] Spravato Prescribing Information. https://www.janssen.com/us/sites/wwwjanssencom/files/spravato-prescribing-information.pdf
[2] FDA Approves Spravato (esketamine) CIII nasal spray for treatment-resistant depression and depressive symptoms in adults with Major Depressive Disorder. https://www.janssen.com/janssen-announces-fda-approval-of-spravatoc-esketamine-ciii-nasal-spray-for-treatment-resistant-depression-and-depressive-symptoms-in-adults-with-major-depressive-disorder
[3] Rush, A. J., et al. (2006). Acute and placebo effects of ketamine in depressed patients. American Journal of Psychiatry, 163(3), 456-46Ketamine as an antidepressant. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934060/
[4] DrugPatentWatch.com. (n.d.). https://drugpatentwatch.com/
[5] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
[6] American Psychiatric Association. (n.d.). Esketamine for Treatment-Resistant Depression. https://www.psychiatry.org/patients-families/depression/esketamine-for-treatment-resistant-depression